Arca Biopharma Up After Safety Panel Gives Nod To Covid: 19 treatment trial

Oruka Therapeutics

29/10/2021 13:51

** Shares of drug developer  ABIO.O  up 12.2% at $2.9
premarket 
    ** Co says Data and Safety Monitoring Committee has
completed interim analysis and recommended completion of
mid-stage study of its COVID-19 treatment with no modifications
to trial design
    ** Co now anticipates completion of target enrollment of 160
patients by year end and topline data from trial in Q1 2022
    ** Up to Thursday's close, stock had fallen 26.8% YTD

 (Reporting by Dania Nadeem in Bengaluru)